Nautilus Biotechnology (NASDAQ:NAUT) Sets New 12-Month Low at $6.90

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) reached a new 52-week low on Monday . The company traded as low as $6.90 and last traded at $7.02, with a volume of 1655 shares changing hands. The stock had previously closed at $7.14.

A number of research analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on Nautilus Biotechnology in a report on Wednesday, August 4th. They issued a “neutral” rating and a $10.00 target price on the stock. Jefferies Financial Group assumed coverage on Nautilus Biotechnology in a report on Tuesday, July 13th. They issued a “buy” rating and a $13.00 target price on the stock.

The stock’s fifty day moving average price is $8.15.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Monday, August 9th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.12). As a group, equities analysts forecast that Nautilus Biotechnology, Inc. will post -0.38 EPS for the current year.

In other Nautilus Biotechnology news, General Counsel Matthew B. Murphy bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 13th. The stock was purchased at an average price of $7.56 per share, for a total transaction of $37,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Anna Mowry bought 17,500 shares of the business’s stock in a transaction that occurred on Thursday, August 12th. The shares were acquired at an average price of $7.71 per share, with a total value of $134,925.00. The disclosure for this purchase can be found here. Insiders bought 47,777 shares of company stock worth $367,204 in the last ninety days.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAUT. Cubist Systematic Strategies LLC purchased a new position in Nautilus Biotechnology during the 2nd quarter valued at approximately $28,000. Penserra Capital Management LLC purchased a new position in Nautilus Biotechnology during the 2nd quarter valued at approximately $48,000. Magnetar Financial LLC purchased a new position in shares of Nautilus Biotechnology in the 2nd quarter worth approximately $108,000. Skye Global Management LP purchased a new position in shares of Nautilus Biotechnology in the 2nd quarter worth approximately $354,000. Finally, Millennium Management LLC bought a new stake in shares of Nautilus Biotechnology during the 2nd quarter worth approximately $385,000. Institutional investors and hedge funds own 26.60% of the company’s stock.

About Nautilus Biotechnology (NASDAQ:NAUT)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.